By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sequenom has sued both Aria Diagnostics and Natera, accusing the companies of infringing a Sequenom patent with their respective noninvasive trisomy 21 and paternity tests.

In its complaint against Aria, filed with the US District Court for the Southern District of California, Sequenom alleges that Aria's prenatal trisomy test infringes its patent, US Patent No. 6,258,540, and that Aria's infringement has been "intentional, deliberate, and willful."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.